Liquid tasimelteon formulations and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12447141-B2
Application number	US-202418947694-A
Country	US
Kind code	B2
Filing date	Nov 14, 2024
Priority date	Dec 13, 2019
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

Liquid suspensions of tasimelteon and methods for their use.

First claim

The invention claimed is:

1. A method of treating a patient with Smith-Magenis Syndrome (SMS), wherein the patient with SMS has a body mass of less than or equal to 28 kg, the method comprising:
administering a dose of tasimelteon orally once daily to the patient that is 0.7 mg/kg.

2. The method of claim 1 , wherein the patient with SMS suffers from nighttime sleep disturbances.

3. The method of claim 2 , wherein the dose of tasimelteon administered to the patient is in a liquid formulation.

4. The method of claim 3 , wherein the liquid formulation is a homogeneous aqueous suspension of tasimelteon and the tasimelteon is present in the liquid formulation at a concentration of 4 mg/mL.

5. The method of claim 3 , wherein the liquid formulation comprises:
a homogeneous aqueous suspension of tasimelteon; and
a suspending agent,
wherein the liquid formulation has a viscosity less than or equal to 150 cps and a specific gravity greater than 1 and up to about 1.5 under ambient conditions.

6. The method of claim 5 , wherein the suspending agent includes at least one cellulosic suspending agent selected from a group consisting of: methylcellulose, hydroxypropyl methylcellulose (HPMC), sodium carboxypropylmethylcellulose (CPMC), carboxymethylcellulose sodium, and microcrystalline cellulose.

7. The method of claim 5 , wherein the liquid formulation further comprises:
a taste-masking agent;
an opacity-imparting agent; and
a surfactant.

8. The method of claim 7 , wherein the liquid formulation further comprises:
a high-intensity sweetener;
an antioxidant;
sodium chloride; and
a flavoring agent.

9. The method of claim 4 , wherein the method includes shaking the liquid formulation for at least 15 seconds before administering to the patient.

10. The method of claim 4 , wherein the method includes shaking the liquid formulation for at least 30 seconds before administering to the patient.

11. The method of claim 2 , wherein nighttime sleep disturbances include at least one sleep disturbance selected from a group consisting of: nighttime activity interrupting the patient's sleep period, poor sleep efficiency, variability in sleep onset, variability in morning awakenings, and poor sleep quality.

12. The method of claim 11 , wherein the dose of tasimelteon is effective to improve the at least one sleep disturbance.

13. The method of claim 12 , wherein the dose of tasimelteon is effective to achieve at least one further improvement selected from a group consisting of: reduced daytime sleepiness, reduced aggressive behavior, reduced temper tantrums, reduced hyperactivity, and reduced attention deficits.

14. A method of treating a patient having a body mass of less than or equal to 28 kg and suffering from nighttime sleep disturbances associated with Smith-Magenis Syndrome, the method comprising:
administering a dose of tasimelteon orally once daily to the patient that is 0.7 mg/kg,
wherein the dose of tasimelteon administered to the patient is in a liquid formulation having a viscosity less than or equal to 150 cps and a specific gravity greater than 1 and up to about 1.5 under ambient conditions, and tasimelteon is present in the liquid formulation at a concentration of 4 mg/mL, the liquid formulation comprising:
a homogeneous aqueous suspension of tasimelteon;
at least one suspending agent selected from a group consisting of:
methylcellulose, hydroxypropyl methylcellulose (HPMC), sodium carboxypropylmethylcellulose (CPMC), carboxymethylcellulose sodium, and microcrystalline cellulose;
a taste-masking agent;
an opacity-imparting agent; and
a surfactant.

15. In a method of administering tasimelteon to a patient suffering from Smith-Magenis Syndrome, the improvement comprising:
selecting for administering a patient with a body mass that is equal to or less than 28 kg; and
administering a dose of tasimelteon orally once daily to the patient that is 0.7 mg/kg.

16. The improvement of claim 15 , wherein the dose of tasimelteon administered to the patient is in a liquid formulation.

17. The improvement of claim 16 , wherein tasimelteon is present in the liquid formulation at a concentration of 4 mg/mL.

18. The improvement of claim 17 , wherein the liquid formulation is a homogeneous aqueous suspension of tasimelteon.

19. The improvement of claim 17 , wherein the liquid formulation comprises:
a homogeneous aqueous suspension of tasimelteon; and
a suspending agent,
wherein the liquid formulation has a viscosity less than or equal to 150 cps and a specific gravity greater than 1 and up to about 1.5 under ambient conditions.

20. The improvement of claim 19 , wherein the suspending agent includes at least one cellulosic suspending agent selected from a group consisting of: methylcellulose, hydroxypropyl methylcellulose (HPMC), sodium carboxypropylmethylcellulose (CPMC), carboxymethylcellulose sodium, and microcrystalline cellulose.

21. The improvement of claim 19 , wherein the liquid formulation further comprises:
a taste-masking agent;
an opacity-imparting agent; and
a surfactant.

22. The improvement of claim 21 , wherein the liquid formulation further comprises:
a high-intensity sweetener;
an antioxidant;
sodium chloride; and
a flavoring agent.

23. The improvement of claim 18 , further comprising:
shaking the liquid formulation for at least 15 seconds before administering to the patient.

24. The improvement of claim 18 , further comprising:
shaking the liquid formulation for at least 30 seconds before administering to the patient.

25. A method of treating a patient suffering from nighttime sleep disturbances associated with Smith-Magenis Syndrome, the method comprising:
determining a body mass of the patient; and
administering a dose of tasimelteon orally once daily to the patient with Smith-Magenis Syndrome, wherein the tasimelteon is present in a liquid formulation at a concentration of 4 mg/mL, wherein the liquid formulation comprises a homogeneous aqueous suspension of tasimelteon, and
in the case that the body mass of the patient is less than or equal to 28 kg, the dose of tasimelteon administered to the patient is 0.7 mg/kg; or
in the case that the body mass of the patient is greater than 28 kg, the dose of tasimelteon administered to the patient is 20 mg.

Assignees

• Vanda Pharmaceuticals Inc

Inventors

• Phadke Deepak
• Polymeropoulos Mihael

Classifications

• A61K47/38

  Cellulose; Derivatives thereof · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title